- Home
- AVB vs INSM Comparison
AVB vs INSM Comparison
Compare AVB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVB
- INSM
- Stock Information
- Founded
- AVB 1978
- INSM 1988
- Country
- AVB United States
- INSM United States
- Employees
- AVB N/A
- INSM N/A
- Industry
- AVB Real Estate Investment Trusts
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- AVB Real Estate
- INSM Health Care
- Exchange
- AVB Nasdaq
- INSM Nasdaq
- Market Cap
- AVB 26.5B
- INSM 26.0B
- IPO Year
- AVB 1994
- INSM 2000
- Fundamental
- Price
- AVB $193.74
- INSM $131.88
- Analyst Decision
- AVB Hold
- INSM Strong Buy
- Analyst Count
- AVB 15
- INSM 19
- Target Price
- AVB $224.33
- INSM $139.31
- AVG Volume (30 Days)
- AVB 985.7K
- INSM 3.2M
- Earning Date
- AVB 07-30-2025
- INSM 08-07-2025
- Dividend Yield
- AVB 3.68%
- INSM N/A
- EPS Growth
- AVB 37.52
- INSM N/A
- EPS
- AVB 8.13
- INSM N/A
- Revenue
- AVB $3,020,968,000.00
- INSM $398,105,000.00
- Revenue This Year
- AVB $3.46
- INSM $28.23
- Revenue Next Year
- AVB $5.15
- INSM $119.99
- P/E Ratio
- AVB $23.41
- INSM N/A
- Revenue Growth
- AVB 5.87
- INSM 21.15
- 52 Week Low
- AVB $180.40
- INSM $60.40
- 52 Week High
- AVB $239.29
- INSM $133.56
- Technical
- Relative Strength Index (RSI)
- AVB 51.73
- INSM 83.97
- Support Level
- AVB $189.14
- INSM $126.00
- Resistance Level
- AVB $193.90
- INSM $130.13
- Average True Range (ATR)
- AVB 3.26
- INSM 4.01
- MACD
- AVB 1.00
- INSM 1.18
- Stochastic Oscillator
- AVB 89.09
- INSM 93.95
About AVB AvalonBay Communities Inc.
AvalonBay Communities owns a portfolio of 290 apartment communities with over 88,000 units and is developing 19 additional properties with over 6,500 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.